Skip to main content

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $10M Private Placement

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has closed on its previously announced private placement. The placement was comprised of the purchase and sale of one million shares of common stock (or prefunded warrants in lieu thereof) at a purchase price of $10 per share (or prefunded warrants in lieu thereof) and accompanying warrant, priced at-the-market under NASDAQ rules. According to the announcement, the shares of common stock (or prefunded warrants) were offered together with warrants to purchase one share of common stock at an exercise price of $10 per share. The warrants will be exercisable upon issuance with an expiration date of five and one-half years from the date of issuance. Gross proceeds from the placement totaled $10 million before standard deductions and offering expenses. The company noted that it anticipates using the net proceeds for working capital and other general corporate needs. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/BFRh6

About Aditxt Inc.

Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. The company’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders that inform and inspire that mission. Aditxt’s diverse innovation portfolio includes Adimune Inc.(TM), aimed at developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity and allergies; Adivir Inc.(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta Inc.(TM), which offers personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.